HeartBeam (BEAT)
NASDAQ:BEAT
Want to see BEAT full AI Analyst Report?
Earnings Data
Report Date
Aug 06, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.09Last Year’s EPS
-0.15Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed meaningful operational progress across multiple fronts — financing closed to extend runway, prototype completion and pilot initiations for the 12‑lead patch, enrollment momentum in ALIGN‑ACS, strategic Mount Sinai AI collaboration, and initial commercial anchor partnerships in four target geographies. At the same time, the company remains an early‑stage commercial operation with a Q1 net loss of $4.7M, limited near‑term revenue, reliance on future studies and regulatory approvals for MI indication, and continued cash consumption (though operating cash burn improved 19% YoY and full‑year outflow guidance was reduced to under $16M). On balance, the highlights (funding, clinical progress, partnerships, prototype, AI collaboration, reduced burn) outweigh the lowlights (losses, limited revenue, regulatory and adoption risk), yielding a cautiously positive outlook as the company advances toward de‑risking key milestones.Company Guidance
Strengthened Balance Sheet via Financing
Closed an underwritten public offering on April 16, 2026 with total gross proceeds of $11.5 million ($10.0M initial offering + $1.5M overallotment). Pro forma cash balance is approximately $12.4 million, extending runway into 2027.
Reduced Operating Cash Burn Year-over-Year
Q1 2026 net cash used in operating activities was $3.6 million, representing a 19% decrease in operating cash outflow versus the same quarter in the prior year.
Commercial Partnerships and Market Footprint
Signed first commercial partnership in Q1 with ClearCardio (New York City, Dallas, South Florida) and added Atelier Health (Beverly Hills/Cedars-Sinai affiliate), establishing flagship presence in all 4 target geographies and initial foothold in the Direct Pay concierge segment (~5 million U.S. patients).
Working Prototype and Patch Pilot Initiated
Completed a working prototype of the on-demand 12-lead patch in Q1 and initiated a European pilot ischemia study (~50 high-risk patients undergoing exercise stress testing) to compare synthesized 12-lead ECGs to standard 12-lead ECGs.
Progress on Heart Attack Detection Clinical Program
Enrolled the first patient in the ALIGN-ACS pilot study (100–120 patients expected); enrollment is ahead of schedule and expected to complete by end of Q3 2026. Additional HEADSTART-ACS study in Indonesia planned (~500 patients) largely government-funded.
Regulatory & Clinical De-risking
Already achieved two FDA clearances for arrhythmia assessment for the HeartBeam system, supporting limited commercial launch and providing a regulatory foundation for future indication expansion.
Strategic AI Collaboration
Finalized a strategic collaboration with Mount Sinai to develop next-generation AI algorithms for MI detection, wellness and personalized cardiac assessment leveraging HeartBeam's 3D ECG signal collection.
Capital-Efficient Commercial Launch Strategy and Pricing
Adopting a lean, focused launch (sales director + implementation specialist per geography initially) targeting concierge/preventive practices. Pricing framework remains at approximately $750–$1,000 annual subscription; management expects many customers to pay year-one fees upfront.
BEAT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
BEAT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 13, 2026 | $1.01 | $1.04 | +2.97% |
Mar 12, 2026 | $1.47 | $1.36 | -7.48% |
Nov 13, 2025 | $1.57 | $1.56 | -0.64% |
Aug 13, 2025 | $1.20 | $1.11 | -7.50% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does HeartBeam (BEAT) report earnings?
HeartBeam (BEAT) is schdueled to report earning on Aug 06, 2026, After Close (Confirmed).
What is HeartBeam (BEAT) earnings time?
HeartBeam (BEAT) earnings time is at Aug 06, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BEAT EPS forecast?
BEAT EPS forecast for the fiscal quarter 2026 (Q2) is -0.09.